Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia
about
HIV-1 Nef impairs MHC class II antigen presentation and surface expressionIn vitro correlates of HIV-2-mediated HIV-1 protectionStrong human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte activity in Sydney Blood Bank Cohort patients infected with nef-defective HIV type 1Binding of human immunodeficiency virus type 1 to CD4 and CXCR4 receptors differentially regulates expression of inflammatory genes and activates the MEK/ERK signaling pathway.Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infectionLatent reservoirs of HIV: obstacles to the eradication of virusViral immune evasion due to persistence of activated T cells without effector functionSpontaneous and antigen-induced production of HIV-inhibitory beta-chemokines are associated with AIDS-free statusPossession of human leucocyte antigen DQ6 alleles and the rate of CD4 T-cell decline in human immunodeficiency virus-1 infectionReconsidering early HIV treatment and supervised treatment interruptionsLimited durability of viral control following treated acute HIV infectionMycobacterial immune reconstitution inflammatory syndrome in HIV-1 infection after antiretroviral therapy is associated with deregulated specific T-cell responses: beneficial effect of IL-2 and GM-CSF immunotherapyRole of viral evolutionary rate in HIV-1 disease progression in a linked cohortHIV/AIDS vaccines for Africa: scientific opportunities, challenges and strategiesShould we treat acute HIV infection?Distinct roles of CD4+ T cell subpopulations in retroviral immunity: lessons from the Friend virus mouse modelCD4 T-cell immunotherapy for chronic viral infections and cancerA Chimeric HIV-1 gp120 Fused with Vaccinia Virus 14K (A27) Protein as an HIV ImmunogenImmunogenicity of seven new recombinant yellow fever viruses 17D expressing fragments of SIVmac239 Gag, Nef, and Vif in Indian rhesus macaquesA new adenovirus based vaccine vector expressing an Eimeria tenella derived TLR agonist improves cellular immune responses to an antigenic targetFunctional impairment of central memory CD4 T cells is a potential early prognostic marker for changing viral load in SHIV-infected rhesus macaquesHuman Immunodeficiency Virus Type 1-Hepatitis C Virus Coinfection: Intraindividual Comparison of Cellular Immune Responses against Two Persistent VirusesBroad Specificity of Virus-Specific CD4+ T-Helper-Cell Responses in Resolved Hepatitis C Virus InfectionGenealogical evidence for positive selection in the nef gene of HIV-1Impaired Hepatitis C Virus-Specific T Cell Responses and Recurrent Hepatitis C Virus in HIV CoinfectionElevations in IL-10, TNF-alpha, and IFN-gamma from the earliest point of HIV Type 1 infectionImmunogenicity and immune modulatory effects of in silico predicted L. donovani candidate peptide vaccinesHighly active antiretroviral therapy in human immunodeficiency virus type 1-infected children: analysis of cellular immune responsesImmunotherapy with canarypox vaccine and interleukin-2 for HIV-1 infection: termination of a randomized trialControl of viremia and prevention of AIDS following immunotherapy of SIV-infected macaques with peptide-pulsed bloodAssociation of differentiation state of CD4+ T cells and disease progression in HIV-1 perinatally infected childrenModeling of HIV-1 infection: insights to the role of monocytes/macrophages, latently infected T4 cells, and HAART regimesIntegrated analysis of residue coevolution and protein structures capture key protein sectors in HIV-1 proteinsPre-existing adenovirus immunity modifies a complex mixed Th1 and Th2 cytokine response to an Ad5/HIV-1 vaccine candidate in humansA vaccine encoding conserved promiscuous HIV CD4 epitopes induces broad T cell responses in mice transgenic to multiple common HLA class II moleculesEfficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trialPD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progressionNef-induced CD4 and major histocompatibility complex class I (MHC-I) down-regulation are governed by distinct determinants: N-terminal alpha helix and proline repeat of Nef selectively regulate MHC-I trafficking.T-helper-cell proliferative responses to whole-killed human immunodeficiency virus type 1 (HIV-1) and p24 antigens of different clades in HIV-1-infected subjects vaccinated with HIV-1 immunogen (Remune)Expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 subtype B pol and gagpol DNA vaccines
P2860
Q22248080-F4A58652-DFAD-43AF-B440-0F36D14B4A3BQ22254217-F441EEB8-683E-46DA-8652-538677226E78Q24516944-7B00B1EF-46EA-48C3-ACA6-1FACC6059C78Q24523390-F29DD869-010E-464A-B741-B820DB927720Q24536249-5BFC4D53-C9AF-4701-A524-22DD4B0EB620Q24615570-A8027742-F672-46BB-9773-6D639C530353Q24646943-DD167CE3-AA19-4D30-BDD2-4F8EBD820F17Q24672737-82E69523-D129-4E3A-9143-E4728A5C1208Q24682861-15E2E781-9885-470B-8254-BA9B23A3389AQ24796745-443319A9-28E8-49E3-BD5D-2AF953171C63Q24804986-EAE7E66D-206B-4EE9-BF3E-01C595170B8EQ24815428-5B81D646-86F0-4307-BC12-DFBC0309A5DBQ24815853-B9EED46F-53D7-44F1-9968-DBE34F8C92F1Q26799624-3E224591-42B5-4280-AC92-2B476A026985Q26826523-5521CF34-80AA-498E-9EF2-B6122997D6BAQ27003380-9B848976-4ACF-48F4-9E4F-1700F5952F67Q27022957-E9B8FA19-79A4-4124-89CD-EB3285B56450Q27302081-787A0EF5-6021-4B12-8E33-8DDE878B5169Q27319783-A1A4ACF0-960A-4EC3-916E-2ADA3E86CDD2Q27333475-5066B5F0-9F27-4AF9-9991-212D8118BF01Q27342763-D2C13291-D108-46DA-9AD3-2877EF5B9DE9Q27472844-9B9E49A4-CE0B-44EA-9291-5AD8FF400198Q27472915-8BEB9422-44EA-4002-A85C-2E3C893CCA53Q27473192-154FF2E6-F10E-4412-BFEA-0F161728D222Q27477797-2C288594-7595-4203-B8D9-F101B97A2AD1Q27486378-04351E72-83FD-4EA7-B334-0CEF4AE3BEC0Q28273639-AD890CC7-5E0B-474F-8469-8B8306F53250Q28347291-58CAC5C9-38BE-4436-A832-7E45BF45000CQ28469122-58948F22-9078-46D6-9B70-AD9E4F55D840Q28472597-AAC31A11-D15C-4E3D-AF4E-4ECABB90058CQ28478811-1336F7B5-553C-409C-AD7F-025F78A8127EQ28484046-1ABB021D-89A6-472B-9E34-5553CB6D43D1Q28543396-5C8AB357-BCA8-42A4-8E54-5A319FB53862Q28741103-4595BD05-1BC7-4FC5-8CF3-9F69456BCC8EQ28751663-7E455BB6-91C5-4C95-9547-575A74C75C1AQ28972526-944A19BF-61E9-4038-B789-35E71F383479Q29618956-9F3ADD73-338B-4DEC-8E14-4868B47A16DEQ30175880-EA26D0C7-0F74-40AB-BE5A-F2B2ED50D2BCQ30327166-12442632-5CB9-48C7-8827-F2E20B389A4BQ30332833-224F6F9C-D192-463D-98F7-3C3482A751B7
P2860
Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia
description
1997 nî lūn-bûn
@nan
1997 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia
@ast
Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia
@en
Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia
@nl
type
label
Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia
@ast
Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia
@en
Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia
@nl
prefLabel
Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia
@ast
Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia
@en
Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia
@nl
P2093
P3181
P1433
P1476
Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia
@en
P2093
A M Caliendo
B D Walker
E S Rosenberg
J M Billingsley
S A Kalams
S L Boswell
P304
P3181
P356
10.1126/SCIENCE.278.5342.1447
P407
P577
1997-11-21T00:00:00Z